Company intelligence / Profile preview

High Everest Capital

Shanghai, China

Ownership: Private
Development stage: Other

Overview

High Everest Capital is a venture capital firm that focuses on early-stage and growth-stage investments within the healthcare and life sciences sectors. The firm typically targets innovative companies developing novel therapeutics, medical devices, and digital health solutions, particularly those with a focus on the Chinese and global markets. By providing both capital and strategic guidance, High Everest Capital aims to accelerate the commercialization of breakthrough medical technologies. Their portfolio often includes companies specializing in oncology, immunology, and metabolic diseases.

Industry: Investors

Beyond the preview

Go deeper on High Everest Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on High Everest Capital.

Explore the full profile